Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

SARS-CoV-2 is an extremely contagious respiratory virus causing adult atypical pneumonia
COVID-19 with severe acute respiratory syndrome (SARS). SARS-CoV-2 has a single …

Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the
treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA …

The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …

DNA and RNA play fundamental roles in various cellular processes, where their three-
dimensional structures provide information critical to understanding the molecular …

The development of effective antiviral therapy for COVID-19 is critical for those awaiting
vaccination, as well as for those who do not respond robustly to vaccination. This review …

The guanosine analog AT-527 represents a promising candidate against Severe Acute
Respiratory Syndrome coronavirus type 2 (SARS-CoV-2). AT-527 recently entered phase III …

The SARS-CoV-2 pandemic is considered as one of the most disastrous pandemics for
human health and the world economy. RNA-dependent RNA polymerase (RdRp) is one of …

The outbreak of COVID-19 caused by SARS-coronavirus (CoV)-2 has made millions of
deaths since 2019. Although a variety of computational methods have been proposed to …

Broad‐spectrum antiviral agents targeting viral RNA‐dependent RNA polymerase (RdRp)
are expected to be a key therapeutic strategy in the ongoing coronavirus disease 2019 …